Mechanism of hypertension and proteinuria during angiogenesis inhibition: Evolving role of endothelin-1

Journal of Hypertension

Volumn 31, Issue 3, 2013, Pages 444-454

  Lankhorst, Stephanie ^a   Kappers, Mariëtte H W ^a,b   Van Esch, Joep H M ^a   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

Endothelin 1; Hypertension; Nitric oxide; Proteinuria; Rarefaction; Soluble vascular endothelial growth factor type 1 receptor; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRASENTAN; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CEDIRANIB; CYCLOHEXIMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; LINIFANIB; MACITENTAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAZOPANIB; SODIUM CHLORIDE; SORAFENIB; SUNITINIB; TELATINIB; TEZOSENTAN; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; BREAST CANCER; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIUM CELL; EYE DISEASE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY METASTASIS; NEOPLASM; NEPHROTIC SYNDROME; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RETINA MACULA DEGENERATION; REVIEW; SALT INTAKE; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SYSTOLIC HYPERTENSION; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ENDOTHELIN-1; HUMANS; HYPERTENSION; PROTEINURIA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877023514     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835c1d1b     Document Type: Review

References (120)

1. Kappers MH, van Esch JHM, Sleijfer S, Danser AHJ, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens 2009; 27:2297-2309.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974. (Pubitemid 43093963)
3. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract 2011; 2011:816897.
4. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 2009; 15:5947-5949.
5. Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 2011; 80:1271-1277.
6. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011; 25:159-169.
7. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49:186-193. (Pubitemid 46178407)
8. Karumanchi SA, Lindheimer MD. Preeclampsia pathogenesis: 'triple a rating'-autoantibodies and antiangiogenic factors. Hypertension 2008; 51:991-992. (Pubitemid 351398952)
9. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
10. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-649. (Pubitemid 43865232)
11. Kappers MH, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56:675-681.
12. George EM, Granger JP. Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension 2012; 60:507-511.
13. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011; 24:964-969.
14. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380. (Pubitemid 35266299)
15. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8:579-591.
16. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611. (Pubitemid 39099316)
17. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4 (Suppl 2):S62-S68. (Pubitemid 39440145)
18. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475-485. (Pubitemid 46809172)
19. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34:1785-1788.
20. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54:652-658.
21. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683. (Pubitemid 38364626)
22. Carmeliet P, Collen D. Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis 1996; 26 (Suppl 4):132-153. (Pubitemid 26417432)
23. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998; 140:947-959. (Pubitemid 28141231)
24. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108 (Pt 6):2369-2379.
25. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H560-H576.
26. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703. (Pubitemid 47268059)
27. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111:707-716. (Pubitemid 36278589)
28. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006; 12:4421s-4425s. (Pubitemid 44197192)
29. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012; 32:434-457.
30. Stewart MW. Bevacizumab for retinopathy of prematurity. Ophthalmology 2012; 119:1091-1092.
31. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6:569-579.
32. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010; 11:1943-1955.
33. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012; 13:585-591.
34. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-1795. (Pubitemid 46912024)
35. Kappers MH, van Esch JHM, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 2011; 96:3087-3094.
36. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010; 30:591-601.
37. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762. (Pubitemid 47356612)
38. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
39. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011; 6:253-258.
40. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24:1363-1369. (Pubitemid 46621999)
41. Kappers MH, Smedts FM, Horn T, van Esch JHM, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58:295-302.
42. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596-604.
43. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15:6250-6257.
44. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56:1131-1136.
45. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6:327-338.
46. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced nonsmall-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28:949-954.
47. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009; 20:393-394.
48. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007; 18:1117. (Pubitemid 47050505)
49. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20:227-230.
50. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001; 98:2604-2609. (Pubitemid 32209529)
51. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 2006; 145:702-703. (Pubitemid 46768848)
52. Gurevich F, Perazella MA. Renal effects of antiangiogenesis therapy: update for the internist. Am J Med 2009; 122:322-328.
53. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21:1381-1389.
54. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100:282-284. (Pubitemid 351480534)
55. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2011; 117:c312-c319.
56. Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24:682-685.
57. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010; 5:477-483.
58. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799. (Pubitemid 46224178)
59. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49:e23-e29. (Pubitemid 46164815)
60. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-1136. (Pubitemid 351398487)
61. Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22:1481-1482.
62. Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8:177-178. (Pubitemid 46158384)
63. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278:12605-12608. (Pubitemid 36800018)
64. Altchek A, Albright NL, Sommers SC. The renal pathology of toxemia of pregnancy. Obstet Gynecol 1968; 31:595-607.
65. Pirani CL, Pollak VE, Lannigan R, Folli G. The renal glomerular lesions of pre-eclampsia: electron microscopic studies. Am J Obstet Gynecol 1963; 87:1047-1070.
66. Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 1991; 17:144-148.
67. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274:H1054-H1058.
68. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999; 274:33057-33063. (Pubitemid 129535347)
69. Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41:773-780. (Pubitemid 29130642)
70. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399:601-605.
71. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 2011; 58:85-92.
72. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14:3470-3476.
73. Kappers MH, de Beer VJ, Zhou Z, Danser AHJ, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59:151-157.
74. Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to anti-angiogenic therapy in a mouse model? Radiology 2009; 251:731-742.
75. de Boer MP, van der Veldt AA, Lankheet NA, Wijnstok NJ, van den Eertwegh AJ, Boven E, Serne EH. Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon. Ann Oncol 2010; 21:1923-1924.
76. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19:927-934. (Pubitemid 351627309)
77. van der Veldt AA, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJ, van Hinsbergh VW, et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs 2010; 21:439-446.
78. van den Meiracker AH, Danser AHJ, Sleijfer S, Kappers MH. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103:1557; author reply 1558.
79. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256:H126-H131.
80. Debbabi H, Uzan L, Mourad JJ, Safar M, Levy BI, Tibirica E. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens 2006; 19:477-483.
81. van Mourik JA, Romani de Wit T, Voorberg J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 2002; 117:113-122.
82. Khimji AK, Rockey DC. Endothelin: biology and disease. Cell Signal 2010; 22:1615-1625.
83. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735. (Pubitemid 120015148)
84. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267:16066-16068.
85. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007; 5:45-52.
86. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, et al. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol 2009; 53:173-178.
87. Kamoi K, Sudo N, Ishibashi M, Yamaji T. Plasma endothelin-1 levels in patients with pregnancy-induced hypertension. N Engl J Med 1990; 323:1486-1487. (Pubitemid 20384965)
88. Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in preeclamptic women. J Obstet Gynaecol Res 2008; 34:957-963.
89. Baksu B, Davas I, Baksu A, Akyol A, Gulbaba G. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. Int J Gynaecol Obstet 2005; 90:112-117. (Pubitemid 40981947)
90. Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD. Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 1991; 165:724-727.
91. Jha V, Aggarwal PK, Chandel N, Jain V. Angiogenic balance and diagnosis of preeclampsia: selecting the right VEGF receptor. J Hum Hypertens 2012; 26:205-206.
92. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55:394-398.
93. Matsuura A, Yamochi W, Hirata K, Kawashima S, Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998; 32:89-95. (Pubitemid 28324130)
94. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008; 52:452-459.
95. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85:587-590. (Pubitemid 20070070)
96. Labonte J, Brochu I, Simard E, D'Orleans-Juste P. Distinct modulation of the endothelin-1 pathway in iNOS-/- and eNOS-/- mice. Can J Physiol Pharmacol 2008; 86:516-525.
97. Weng YH, Kuo CY, Chiu YW, Kuo ML, Liao SL. Alteration of nitric oxide gas on gene expression of endothelin-1 and endothelial nitric oxide synthase by a time- and dose-dependent manner in human endothelial cells. Chin J Physiol 2009; 52:59-64.
98. Mitsutomi N, Akashi C, Odagiri J, Matsumura Y. Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells. Eur J Pharmacol 1999; 364:65-73. (Pubitemid 29015788)
99. Filep JG. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension 1997; 30:22-28. (Pubitemid 27306342)
100. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995; 91:771-775.
101. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000; 35:1237-1241. (Pubitemid 30413657)
102. Hall JE, Guyton AC, Brands MW. Pressure-volume regulation in hypertension. Kidney Int Suppl 1996; 55:S35-41.
103. Gu JW, Manning RD Jr, Young E, Shparago M, Sartin B, Bailey AP. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol 2009; 297:R142-R148.
104. Granger JP. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension 2009; 54:465-467.
105. Leonard AM, Chafe LL, Montani JP, Van Vliet BN. Increased salt-sensitivity in endothelial nitric oxide synthase-knockout mice. Am J Hypertens 2006; 19:1264-1269. (Pubitemid 44856255)
106. Manning RD Jr, Hu L, Tan DY, Meng S. Role of abnormal nitric oxide systems in salt-sensitive hypertension. Am J Hypertens 2001; 14:68S-73S. (Pubitemid 32506699)
107. Kopkan L, Hess A, Huskova Z, Cervenka L, Navar LG, Majid DS. High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. Am J Physiol Renal Physiol 2010; 299:F656-F663.
108. Inscho EW, Imig JD, Cook AK, Pollock DM. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol 2005; 146:1019-1026. (Pubitemid 41722175)
109. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009; 15:545-552.
110. Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension 2010; 55:755-761.
111. Schulz E, Jansen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10:1115-1126. (Pubitemid 351451710)
112. Henao DE, Saleem MA, Cadavid AP. Glomerular disturbances in preeclampsia: disruption between glomerular endothelium and podocyte symbiosis. Hypertens Pregnancy 2010; 29:10-20.
113. Gerke P, Sellin L, Kretz O, Petraschka D, Zentgraf H, Benzing T, Walz G. NEPH2 is located at the glomerular slit diaphragm, interacts with nephrin and is cleaved from podocytes by metalloproteinases. J Am Soc Nephrol 2005; 16:1693-1702. (Pubitemid 41716475)
114. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, Camussi G. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008; 294:F1185-F1194.
115. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20:807-815.
116. Molteni A, Heffelfinger S, Moulder JE, Uhal B, Castellani WJ. Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem 2006; 6:451-460. (Pubitemid 44377779)
117. Blanco S, Bonet J, Lopez D, Casas I, Romero R. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl 2005:S10-S14. (Pubitemid 40019208)
118. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008; 40:1443-1451.
119. Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E. Targeting the endothelin axis in prostate carcinoma. Tumour Biol 2012; 33:421-426.
120. Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, et al. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer 2012; 106:284-289.